Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g Vct5 Regulatory News (MIG5)

Share Price Information for Maven I&g Vct5 (MIG5)

Share Price is delayed by 15 minutes
Get Live Data
28.80    0.00 (0.00%)
Bid:
27.80
Ask:
29.80
Spread: 2.00 (7.194%)
Market Cap: £76.28m
MIG5 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g Vct5 Share Chart

Directorate Change

3 Jun 2013 07:00

RNS Number : 0304G
Maven Income and Growth VCT 5 PLC
03 June 2013
 



 

Maven Income and Growth VCT 5 PLC

 

Directorate Changes

 

The Board of Maven Income and Growth VCT 5 PLC is pleased to announce the appointment of Mr Allister Langlands and Mr Charles Young as Non-executive Directors with effect from 1 June 2013. Mr Langlands and Mr Young will also both serve on the Company's Audit, Management Engagement, Nomination and Remuneration Committees.

 

Mr Langlands is Chairman of John Wood Group PLC, having served as chief executive from 2007 to 2012 and previously as deputy chief executive from 1999 and as group finance director from 1991.

 

Allister has an MA (Hons) in Economics from the University of Edinburgh and completed the Harvard Advanced Management Program in 1999. He is also a member of the Institute of Chartered Accountants of Scotland, having trained with Deloitte Haskins & Sells (now PricewaterhouseCoopers) before being made a partner in 1989.

 

Mr Young is chief executive of E G Thomson (Holdings) Limited, a private investment company. He is also a non-executive director of Ben Line Agencies Limited and Exakt Precision Tools Limited, and his recent former directorships include Minoan Group Plc.

 

Charles is a Bachelor of Laws and is a member of the Institute of Chartered Accountants of Scotland, having trained with Arthur Young McClelland Moores & Co (now part of Ernst & Young). He was employed by The British Linen Bank Limited between 1979 and 1997, serving as a main board director from 1991 until 1997, as a director of its corporate finance division from 1986 to 1992 and as managing director of its private equity operations from 1992 to1997.

 

In relation to either of these appointments, there is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 R.

 

These appointments are part of a succession plan, announced on 18 March 2013, for which the Board has considered a number of candidates with the intention that one or more of the then Directors would step down between the Annual General Meetings to be held in 2013 and 2014 in order to allow new Board members to be appointed. Each new Director will be subject to re-election by Shareholders at the first Annual General Meeting following their appointment and confirmation of any further changes to the constitution of the Board will be communicated fully to Shareholders in due course.

 

Maven Capital Partners UK LLP

Secretary

3 June 2013

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAFFLFXXEFEBBE
Date   Source Headline
20th May 202610:20 amRNSAdmission of Further Securities to Trading
15th May 202610:10 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20263:39 pmRNSUnaudited NAV - Dividend Investment Scheme
8th May 20264:10 pmRNSTransaction in Own Shares
28th Apr 20263:55 pmRNSResult of AGM
28th Apr 20261:35 pmRNSResult of AGM
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:30 amRNSAdmission of Further Securities to Trading
14th Apr 202611:11 amRNSIssue of Equity
8th Apr 20269:35 amRNSAdmission of Further Securities to Trading
27th Mar 20265:07 pmRNSOffer for Subscription - Fully Subscribed
25th Mar 202610:59 amRNSAdmission of Further Securities to Trading
25th Mar 20267:00 amRNSAnnual Financial Report
24th Mar 202612:13 pmRNSIssue of Equity
17th Mar 20264:36 pmRNSUnaudited Net Asset Value
3rd Mar 20264:31 pmRNSTransaction in Own Shares - correction
27th Feb 20265:04 pmRNSTransaction in Own Shares
26th Feb 20264:53 pmRNSTransaction in Own Shares
26th Feb 20269:15 amRNSDividend Declaration
18th Feb 20265:01 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:11 amRNSDirector/PDMR Shareholding
17th Feb 202610:58 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:13 amRNSAdmission of Further Securities to Trading
16th Jan 20269:47 amRNSIssue of Equity
14th Jan 20262:44 pmRNSUnaudited NAV - Dividend Investment Scheme
16th Dec 202511:15 amRNSDirector/PDMR Shareholding
16th Dec 202510:30 amRNSIssue of Equity
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20253:45 pmRNSResult of General Meeting
7th Oct 20254:15 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:11 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:17 pmRNSStatement re Dividend Investment Scheme
17th Jul 20253:21 pmRNSHalf-year Report
16th Jul 20255:33 pmRNSTransaction in Own Shares
16th Jul 20257:08 amRNSStatement re Offer for Subscription
10th Jul 20254:50 pmRNSStatement re Unaudited NAV and Interim Dividend
14th May 20254:46 pmRNSTransaction in Own Shares
9th May 20259:59 amRNSIssue of Equity
6th May 202511:55 amRNSIssue of Equity
2nd May 20251:27 pmRNSUnaudited NAV - Dividend Investment Scheme
29th Apr 20253:20 pmRNSResult of AGM
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
15th Apr 20259:32 amRNSDirector/PDMR Shareholding
4th Apr 20256:22 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:14 pmRNSDirector/PDMR Shareholding
27th Mar 20251:09 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.